Crizotinib: a breakthrough for targeted therapies in lung cancer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4093347 | PMC |
| http://dx.doi.org/10.6004/jadpro.2012.3.4.8 | DOI Listing |
Similar Publications
Emerging EGFR-Mutated Subclones in a Patient With Metastatic ALK-Rearranged Lung Adenocarcinoma Treated With ALK-Targeted Therapy: A Case Report.
JTO Clin Res Rep
July 2023
Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong Special Administrative Region, People's Republic of China.
We report a case of pathologically confirmed ALK-rearranged metastatic lung adenocarcinoma with emergence of EGFR L858R mutation on disease progression after two lines of treatment with ALK inhibitors. At initial diagnosis, tumoral ALK expression was detected without EGFR mutation by standard allele-specific polymerase chain reaction. There was sustained partial response to both first-line crizotinib and subsequent brigatinib.
View Article and Find Full Text PDFCase report: complete remission with crizotinib in fusion-positive sinonasal mucosal melanoma.
Front Oncol
October 2022
Sir Run Run Shaw Hospital, Medical School of Zhejiang University, Hangzhou, China.
Introduction: Sinonasal mucosal melanoma (SNMM) originates from melanocytes. Currently, the main treatment methods, including surgery, radiotherapy and chemotherapy, have little effect on the recurrence and metastasis of SNMM. However, targeted therapy may be a breakthrough in treating SNMM.
View Article and Find Full Text PDFStructural binding site comparisons reveal Crizotinib as a novel LRRK2 inhibitor.
Comput Struct Biotechnol J
June 2021
Biotechnology Center (BIOTEC), Technische Universität Dresden, Tatzberg 47/49, Dresden 01307, Germany.
Mutations in leucine-rich repeat kinase 2 (LRRK2) are a frequent cause of autosomal dominant Parkinson's disease (PD) and have been associated with familial and sporadic PD. Reducing the kinase activity of LRRK2 is a promising therapeutic strategy since pathogenic mutations increase the kinase activity. Several small-molecule LRRK2 inhibitors are currently under investigation for the treatment of PD.
View Article and Find Full Text PDFHydrophobic and polar interactions of FDA-approved small molecule protein kinase inhibitors with their target enzymes.
Pharmacol Res
July 2021
Blue Ridge Institute for Medical Research, 3754 Brevard Road, Suite 116, Box 19, Horse Shoe, NC 28742-8814, United States. Electronic address:
Article Synopsis
- Dysregulation and mutations in protein kinases are key factors in various diseases, especially cancer, highlighting the importance of understanding their interactions and functions.
- The KLIFS catalog identifies crucial ligand binding-site residues in protein kinases that interact with FDA-approved drugs, mainly involving hydrophobic and hydrogen bond interactions at specific residues in both the small and large lobes of these enzymes.
- Ongoing research into protein kinase signaling pathways is expected to lead to new targeted therapies, improving treatment options for a range of health issues.
Efficacy and Safety of Crizotinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with ROS1 Rearrangement or MET Alteration: A Systematic Review and Meta-Analysis.
Target Oncol
October 2020
Department of Pathology, Oklahoma University Health Sciences Center, Oklahoma City, OK, 73104, USA.
Background: Crizotinib has been approved for the treatment of non-small-cell lung cancer (NSCLC) with ROS proto-oncogene 1 (ROS1) gene fusion. This drug has also been granted breakthrough designation for NSCLCs with MET exon 14 alterations.
Objective: This systematic review and meta-analysis aimed to investigate the efficacy and safety of crizotinib in patients with these diseases.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!
© LitMetric 2025. All rights reserved.